Entera Bio (NASDAQ:ENTX) Trading Down 3.1% – Here’s What Happened

Entera Bio Ltd. (NASDAQ:ENTX) was down 3.1% during mid-day trading on Tuesday . The stock traded as low as $1.57 and last traded at $1.57. Approximately 133,504 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 267,867 shares. The stock had previously closed at $1.62.

Analysts Set New Price Targets

Several research firms have weighed in on ENTX. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, December 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Entera Bio Trading Down 3.1%

The business has a 50-day moving average of $2.05 and a 200 day moving average of $2.08. The firm has a market capitalization of $72.00 million, a PE ratio of -6.28 and a beta of 1.78.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. On average, sell-side analysts expect that Entera Bio Ltd. will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Entera Bio stock. Citadel Advisors LLC lifted its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 243.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,978 shares of the company’s stock after purchasing an additional 28,322 shares during the period. Citadel Advisors LLC owned about 0.09% of Entera Bio worth $77,000 at the end of the most recent reporting period. 14.11% of the stock is owned by institutional investors.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.